Filter Results
Related Organization
- Biological and Environmental Systems Science Directorate (29)
- Computing and Computational Sciences Directorate (39)
- Energy Science and Technology Directorate
(229)
- Fusion and Fission Energy and Science Directorate (24)
- Information Technology Services Directorate (3)
- National Security Sciences Directorate (20)
- Neutron Sciences Directorate (11)
- Physical Sciences Directorate (138)
- User Facilities (28)
- (-) Isotope Science and Enrichment Directorate (7)
Researcher
- Alexey Serov
- Jaswinder Sharma
- Mike Zach
- Xiang Lyu
- Amit K Naskar
- Andrew F May
- Annetta Burger
- Ben Garrison
- Beth L Armstrong
- Brad Johnson
- Bruce Moyer
- Carter Christopher
- Chance C Brown
- Charlie Cook
- Christopher Hershey
- Craig Blue
- Daniel Rasmussen
- Debjani Pal
- Debraj De
- Gabriel Veith
- Gautam Malviya Thakur
- Georgios Polyzos
- Holly Humphrey
- Hsin Wang
- James Gaboardi
- James Klett
- James Szybist
- Jeffrey Einkauf
- Jennifer M Pyles
- Jesse McGaha
- John Lindahl
- Jonathan Willocks
- Junbin Choi
- Justin Griswold
- Kevin Sparks
- Khryslyn G Araño
- Kuntal De
- Laetitia H Delmau
- Liz McBride
- Logan Kearney
- Luke Sadergaski
- Marm Dixit
- Meghan Lamm
- Michael Toomey
- Michelle Lehmann
- Nedim Cinbiz
- Nihal Kanbargi
- Padhraic L Mulligan
- Ritu Sahore
- Sandra Davern
- Todd Thomas
- Todd Toops
- Tony Beard
- Xiuling Nie

Free-standing, thin films were fabricated with a binder resulting in nearly an order of magnitude thickness decrease while increasing porosity and activation energy. These effects of such diminished significantly. Free-standing films could be fabricated with a binder.

This technology creates a light and metalless current collector for battery application. Cathodes coated on this new current collector demonstrated similar contact resistance, lower charge transfer resistance and similar or high rate performance.

Biocompatible nanoparticles have been developed that can trap and retain therapeutic radionuclides and their byproducts at the cancer site. This is important to maximize the therapeutic effect of this treatment and minimize associated side effects.

An ORNL team has developed a method for screening for an immunoregulatory protein, which includes assessing the sequence of a candidate protein to determine if it is an immunoregulatory protein when at least one plasminogen-apple-nematode (PAN) domain with a consensus sequence